Moberg Pharma AB (FRA:MB8) Cyclically Adjusted FCF per Share: €-4.02 (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
60 GF Score
Price €0.79
GF Value €1.06
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Cyclically Adjusted FCF per Share?

Moberg Pharma AB FRA:MB8 -2.10% 60 Cyclically Adjusted FCF per Share is €-4.02 as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.06. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Moberg Pharma AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.016. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-4.02 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Moberg Pharma AB was -6.70% per year. The lowest was -6.70% per year. And the median was -6.70% per year.

As of today (2026-07-10), Moberg Pharma AB's current stock price is €0.791. Moberg Pharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-4.02. Moberg Pharma AB's Cyclically Adjusted Price-to-FCF of today is .


Moberg Pharma AB  (FRA:MB8) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Moberg Pharma AB Cyclically Adjusted FCF per Share Related Terms


Moberg Pharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Cyclically Adjusted FCF per Share Chart

Moberg Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.82 -3.71 -4.33 -3.84 0.00

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.95 -3.90 -4.05 -4.05 -4.02

FRA:MB8 vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:MB8
60GF Score
Moberg Pharma AB FRA:MB8
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Moberg Pharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.016/133.5600*133.5600
=-0.016

Current CPI (Mar. 2026) = 133.5600.

Moberg Pharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 -0.064 100.276 -0.085
201603 -0.325 100.751 -0.431
201606 0.056 101.019 0.074
201609 -14.651 101.138 -19.348
201612 -15.709 102.022 -20.565
201703 -0.399 102.022 -0.522
201706 -1.262 102.752 -1.640
201709 1.794 103.279 2.320
201712 0.961 103.793 1.237
201803 -0.572 103.962 -0.735
201806 0.612 104.875 0.779
201809 -0.074 105.679 -0.094
201812 -0.280 105.912 -0.353
201903 0.200 105.886 0.252
201906 -2.608 106.742 -3.263
201909 -1.362 107.214 -1.697
202003 -0.394 106.563 -0.494
202006 -0.669 107.498 -0.831
202009 -0.481 107.635 -0.597
202103 -0.292 108.360 -0.360
202106 -0.128 108.928 -0.157
202109 -0.176 110.338 -0.213
202112 -0.102 112.486 -0.121
202203 -0.400 114.825 -0.465
202206 -0.215 118.384 -0.243
202209 -0.104 122.296 -0.114
202212 -0.104 126.365 -0.110
202303 -0.234 127.042 -0.246
202306 -0.171 129.407 -0.176
202309 -0.110 130.224 -0.113
202312 -0.076 131.912 -0.077
202403 -0.040 132.205 -0.040
202406 -0.076 132.716 -0.076
202409 -0.049 132.304 -0.049
202412 -0.028 132.987 -0.028
202503 -0.046 132.825 -0.046
202506 -0.026 133.699 -0.026
202509 -0.034 133.480 -0.034
202512 -0.009 133.390 -0.009
202603 -0.016 133.560 -0.016

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-4.02 mean?
Moberg Pharma AB (FRA:MB8) has a Cyclically Adjusted FCF per Share of €-4.02 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Cyclically Adjusted FCF per Share too high?
Moberg Pharma AB's current Cyclically Adjusted FCF per Share is €-4.02. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Moberg Pharma AB's Cyclically Adjusted FCF per Share of €-4.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Cyclically Adjusted FCF per Share is €-4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Cyclically Adjusted FCF per Share of €-4.02. The stock's GF Value™ is €1.06, compared to a current price of €0.79 — trading 25.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-4.02. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Cyclically Adjusted FCF per Share is €-4.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.79 is trading 25.4% below its estimated GF Value™ of €1.06.

Key valuation signals for FRA:MB8:

  • Cyclically Adjusted FCF per Share: €-4.02
  • GF Value™: €1.06 vs. price of €0.79 (25.4% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
60GF Score

Get the complete analysis for FRA:MB8

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.06
GF Value